Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress

Phase 4 Recruiting 2270 enrolled Population Health Research Institute Hamilton Health Sciences Corporation · collab

RandomizedParallel-groupSingle-blindPrevention

Summary

Multinational, investigator-initiated study of oral anticoagulation versus no anticoagulation for the prevention of stroke and other adverse cardiovascular events in patients with transient atrial fibrillation occurring transiently with stress and additional stroke risk factors.

Timeline

Start: 2019-06-14
Primary completion: 2028-12
Completion: 2028-12

Publications

Boriani G, Imberti JF, McIntyre WF, Mei DA, Healey JS, Schnabel RB, Svennberg E, Camm AJ, Freedman B. Detection and management of postoperative atrial fibrillation after coronary artery bypass grafting or non-cardiac surgery: a survey by the AF-SCREEN International Collaboration. Intern Emerg Med. 2025 Apr;20(3):739-749. doi: 10.1007/s11739-025-03861-2. Epub 2025 Feb 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Apixaban	Small molecule	2.5 mg	Oral
Subject	Apixaban	Small molecule	5 mg	Oral
Subject	Dabigatran	Unknown	110 mg	Oral
Subject	Edoxaban	Small molecule	30 mg	Oral
Subject	Edoxaban	Small molecule	60 mg	Oral
Subject	Rivaroxaban	Other / unclassified	15 mg	Oral
Subject	Rivaroxaban	Other / unclassified	20 mg	Oral

Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress

Summary

Timeline

Publications

Drugs

Indications